- Home
- EQ vs XBP Comparison
EQ vs XBP Comparison
Compare EQ & XBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQ
- XBP
- Stock Information
- Founded
- EQ 2017
- XBP 2020
- Country
- EQ United States
- XBP United States
- Employees
- EQ N/A
- XBP N/A
- Industry
- EQ Biotechnology: Pharmaceutical Preparations
- XBP Business Services
- Sector
- EQ Health Care
- XBP Consumer Discretionary
- Exchange
- EQ Nasdaq
- XBP Nasdaq
- Market Cap
- EQ 67.9M
- XBP 71.0M
- IPO Year
- EQ 2018
- XBP N/A
- Fundamental
- Price
- EQ $1.88
- XBP $0.75
- Analyst Decision
- EQ Hold
- XBP
- Analyst Count
- EQ 2
- XBP 0
- Target Price
- EQ $1.00
- XBP N/A
- AVG Volume (30 Days)
- EQ 16.1M
- XBP 558.8K
- Earning Date
- EQ 08-14-2025
- XBP 08-14-2025
- Dividend Yield
- EQ N/A
- XBP N/A
- EPS Growth
- EQ N/A
- XBP N/A
- EPS
- EQ N/A
- XBP N/A
- Revenue
- EQ $16,553,000.00
- XBP $148,332,000.00
- Revenue This Year
- EQ N/A
- XBP N/A
- Revenue Next Year
- EQ N/A
- XBP N/A
- P/E Ratio
- EQ N/A
- XBP N/A
- Revenue Growth
- EQ N/A
- XBP 0.23
- 52 Week Low
- EQ $0.27
- XBP $0.42
- 52 Week High
- EQ $2.35
- XBP $2.56
- Technical
- Relative Strength Index (RSI)
- EQ 68.96
- XBP 56.07
- Support Level
- EQ $1.50
- XBP $0.58
- Resistance Level
- EQ $2.35
- XBP $0.63
- Average True Range (ATR)
- EQ 0.35
- XBP 0.06
- MACD
- EQ -0.00
- XBP 0.03
- Stochastic Oscillator
- EQ 62.10
- XBP 95.92
About EQ Equillium Inc.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.
About XBP XBP Europe Holdings Inc.
XBP Global Holdings Inc is a multinational leader in business process automation, serving over 2,500 clients-including more than 30 Fortune 100 companies. Its proprietary software and deep domain expertise position it as a trusted technology and services partner. With cloud-based solutions and a global footprint, XBP Global delivers measurable value, improves advances digital transformation, improves market-wide liquidity by expediting payments, and promotes sustainable business practices.